CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


CA Cancer J Clin 1998; 48:199
doi: 10.3322/canjclin.48.4.199
© 1998 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vikram, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vikram, B.

CA: A Cancer Journal for Clinicians, Vol 48, Issue 4 199-209, Copyright © 1998 by American Cancer Society


ARTICLES

Adjuvant therapy in head and neck cancer

B. Vikram
Unified Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY, USA.

Many challenges remain, but considerable progress has been made in this field since 1983, when we published in this journal an article titled "Adjuvant Radiation Therapy in Locally Advanced Head and Neck Cancer." Several clinical and pathologic features have been identified that can stratify patients according to the risk of relapse (whether at the primary site, in the neck, or at distant sites) or the risk of second cancers, so that additional adjuvant treatment might be administered only to patients who are the most likely to benefit from it. Hope exists that in the near future our capabilities will be bolstered by the availability of powerful new biologic and molecular genetic tools. The greatest advance, perhaps, has been the recognition that adjuvant therapy for head and neck cancer should not be an afterthought but part of a thoughtfully crafted interdisciplinary strategy aimed at maximizing tumor control with the least morbidity.


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
Q. Sun, T. Sakaida, W. Yue, S. M. Gollin, and J. Yu
Chemosensitization of head and neck cancer cells by PUMA
Mol. Cancer Ther., December 1, 2007; 6(12): 3180 - 3188.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by American Cancer Society.